A case-control study of levothyroxine and the risk of colorectal cancer

Journal of the National Cancer Institute

Volumn 102, Issue 8, 2010, Pages 568-572

  Rennert, Gad ^a   Rennert, Hedy S ^a   Pinchev, Mila ^a   Gruber, Stephen B ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ESTROGEN; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE; THYROXINE;

ARTICLE; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; DRUG USE; FAMILY HISTORY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; INTERVIEW; ISRAEL; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; VEGETABLE; AGED; CASE CONTROL STUDY; COLORECTAL TUMOR; EPIDEMIOLOGY; ETHNOLOGY; GENETICS; JEW; METHODOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; STATISTICS;

AGED; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HUMANS; HYPOTHYROIDISM; ISRAEL; JEWS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SELECTION BIAS; THYROXINE;

EID: 77951631921     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq042     Document Type: Article

References (41)

1. Israel National Cancer Registry. Ministry of Health. http://www.health. gov.il/pages/default.asp?maincat=22&catId=56&PageId=688. Accessed July 2009.
2. Jiskra J, Barkmanova J, Limanova Z, et al. Thyroid autoimmunity occurs more frequently in women with breast cancer compared to women with colorectal cancer and controls but it has no impact on relapse-free and overall survival. Oncol Rep. 2007;18(6):1603-1611.
3. Giustarini E, Pinchera A, Fierabracci P, et al. Thyroid autoimmunity in patients with malignant and benign breast diseases before surgery. Eur J Endocrinol. 2006;154(5):645-649. (Pubitemid 43810849)
4. Kuijpens JL, Nyklíctek I, Louwman MW, Weetman TA, Pop VJ, Coebergh JW. Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid. 2005;15(11):1253-1259. (Pubitemid 41821759)
5. Giani C, Fierabracci P, Bonacci R, et al. Relationship between breast cancer and thyroid disease: relevance of autoimmune thyroid disorders in breast malignancy. J Clin Endocrinol Metab. 1996;81(3):990-994. (Pubitemid 26083958)
6. Kapdi CC, Wolfe JN. Breast cancer. Relationship to thyroid supplements for hypothyroidism. JAMA. 1976;236(10):1124-1127.
7. Morabia A, Szklo M, Stewart W, Schuman L, Thomas DB, Zacur HA. Thyroid hormones and duration of ovulatory activity in the etiology of breast cancer. Cancer Epidemiol Biomarkers Prev. 1992;1(5):389-393.
8. Gago-Dominguez M, Castelao JE. Role of lipid peroxidation and oxidative stress in the association between thyroid diseases and breast cancer. Crit Rev Oncol Hematol. 2008;68(2):107-114.
9. Smyth PP. The thyroid and breast cancer: a significant association? Ann Med. 1997;29(3):189-191. (Pubitemid 27292526)
10. Syrigos KN, Konstantoulakis MM, Constantoulakis M, Marafelia P, Koutras D, Golematis BC. Thyroid autoantibodies and thyroid function in patients with gastric cancer. Acta Oncol. 1994;33(8):905-907.
11. Fyssas I, Syrigos KN, Konstantoulakis MM, et al. Thyroid autoantibodies and thyroid function in patients with pancreatic adenocarcinoma. Acta Oncol. 1997;36(1):65-68. (Pubitemid 27135165)
12. Jiskra J, Límanová Z, Barkmanová J, Smutek D, Friedmannová Z. Autoimmune thyroid diseases in women with breast cancer and colorectal cancer. Physiol Res. 2004;53(6):693-702. (Pubitemid 40065700)
13. Natsume H, Sasaki S, Kitagawa M, et al. Beta-catenin/Tcf-1-mediated transactivation of cyclin D1 promoter is negatively regulated by thyroid hormone. Biochem Biophys Res Commun. 2003;309(2):408-413. (Pubitemid 37025905)
14. Poynter JN, Gruber SB, Higgins PDR, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352(21):2184-2192. (Pubitemid 40727085)
15. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr. 1982;36(5):936-942. (Pubitemid 13214364)
16. Yizhaki D, Rennert HS, Rosen G, Rennert G. Validity and reproducibility of a semi-quantitative food frequency questionnaire adapted to an Israeli population. Open Nutr J. 2008;2:9-14.
17. Barchana M, Liphshitz I, Rozen P. Trends in colorectal cancer incidence and mortality in the Israeli Jewish ethnic populations. Fam Cancer. 2004;3(3-4):207-214. (Pubitemid 39491736)
18. Barchana M. Colorectal cancer. In: Freedman LS, Edwards BK, Ries LAG, Young JL, eds. Cancer Incidence in Four Member Countries of the MECC Compared With US SEER. National Cancer Institute MECC Monograph. Publ No. 06-5873. 2006:41-50.
19. Rennert G, Peterburg Y. Prevalence of selected chronic diseases in Israel. Isr Med Assoc J. 2001;3(6):404-408. (Pubitemid 34176916)
20. Kampman E, Potter JD, Slattery ML, Caan BJ, Edwards S. Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States. Cancer Causes Control. 1997;8(2):146-158. (Pubitemid 27170369)
21. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288(7):872-881.
22. Newcomb PA, Zheng Y, Chia VM, et al. Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. Cancer Res. 2007;67(15):7534-7539. (Pubitemid 47206584)
23. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Women's Health Initiative Investigators. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350(10):991-1004. (Pubitemid 38269276)
24. Rennert G, Rennert HS, Pinchev M, Lavi O, Gruber SB. HRT use and risk of colorectal cancer. J Clin Oncol. 2009;27(27):4542-4547.
25. Iishi H, Tatsuta M, Baba M, Yamamoto R, Taniguchi H. Enhancement by thyroxine of gastric carcinogenesis induced by N-methyl-N'-nitro-N- nitrosoguanidine in Wistar rats. Br J Cancer. 1993;68(3):515-518. (Pubitemid 23258454)
26. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-Tumor development. N Engl J Med. 1988;319(9):525-532.
27. Alarid ET, Preisler-Mashek MT, Solodin NM. Thyroid hormone is an inhibitor of estrogen-induced degradation of estrogen receptor-Alpha protein: estrogen-dependent proteolysis is not essential for receptor transactivation function in the pituitary. Endocrinology. 2003;144(8):3469-3476. (Pubitemid 36904424)
28. Chan IH, Privalsky ML. Thyroid hormone receptors mutated in liver cancer function asdistorted antimorphs. Oncogene. 2006;25(25):3576-3588. (Pubitemid 43901679)
29. Cheng SY. Thyroid hormone receptor mutations in cancer. Mol Cell Endocrinol. 2003;213(1):23-30.
30. Chen RN, Huang YH, Yeh CT, Liao CH, Lin KH. Thyroid hormone receptors suppress pituitary tumor transforming gene 1 activity in hepatoma. Cancer Res. 2008;68(6):1697-1706.
31. Dinda S, Sanchez A, Moudgil V. Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene. 2002;21(5):761-768. (Pubitemid 34146288)
32. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-Term effects of hormone replacement therapy. Lancet. 2002;360(9337):942- 944. (Pubitemid 35283842)
33. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356(16):1670-1674. (Pubitemid 46631679)
34. Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La Vecchia C. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer. 2003;105(3):408-412. (Pubitemid 36575452)
35. Fujimoto N, Jinno N, Kitamura S. Activation of estrogen response element dependent transcription by thyroid hormone with increase in estrogen receptor levels in a rat pituitary cell line, GH3. J Endocrinol. 2004;181(1):77-83. (Pubitemid 38584665)
36. Böttner M, Wuttke W. Chronic treatment with low doses of estradiol affects pituitary and thyroid function in young and middle-Aged ovariectomized rats. Biogerontology. 2005;6(4):261-269. (Pubitemid 43118465)
37. Grüning T, Zöphel K, Wunderlich G, Franke WG. Influence of female sex hormones on thyroid parameters determined in a thyroid screening. Clin Lab. 2007;53(9-12):547-553. (Pubitemid 351165864)
38. Schindler AE. Thyroid function and postmenopause. Gynecol Endocrinol. 2003;17(1):79-85. (Pubitemid 36349885)
39. Lecomte P, Lecureuil N, Osorio-Salazar C, Lecureuil M, Valat C. Effects of suppressive doses of levothyroxine treatment on sex-hormone-binding globulin and bone metabolism. Thyroid. 1995;5(1):19-23.
40. Shifren JL, Desindes S, McIlwain M, Doros G, Mazer NA. A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause. 2007;14(6):985-994. (Pubitemid 350098657)
41. Slattery ML, Sweeney C, Murtaugh M, et al. Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(12):2936-2942. (Pubitemid 43068828)